These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1445732)

  • 1. Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
    Kerbrat P; Somers R; Verweij J; Crowther D; Tursz T; Santoro A; Steward WP; Lentz MA; van Glabbeke M; Mouridsen HT
    Eur J Cancer; 1992; 29A(1):143-4. PubMed ID: 1445732
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group.
    Rouëssé JG; van Oosterom AT; Capellaere P; Kerbrat P; van Coninge CJ; Thomas D; Benshahar D
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1413-4. PubMed ID: 3678328
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fotemustine: a pilot phase II trial in sarcoma of the soft tissues].
    Spielmann M; Berille J; Khayat D; Bizzari JP; Jacquillat C; Tursz T
    Bull Cancer; 1991; 78(5):453-6. PubMed ID: 1878607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group).
    Rougier P; van Pottelsberghe C; Kok T; Paillot B; Wagener T; De Greve J; Fabri MC; Gerard B; Van Glabbeke M; Bleiberg H
    Eur J Cancer; 1996 Jul; 32A(8):1432-3. PubMed ID: 8869111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of fotemustine in patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    Invest New Drugs; 1994; 12(3):251-4. PubMed ID: 7896545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
    Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
    Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer.
    Rudd R; Allen R; Berille J; Spiro SG; Trask C; Souhami RL
    Cancer Chemother Pharmacol; 1994; 34(5):444-6. PubMed ID: 8070014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
    Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
    Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma.
    Le Chevalier T; Zabbe C; Gouva S; Cerrina ML; Quoix E; Riviere A; Berthaud P; Prache C; Berille J
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1651-2. PubMed ID: 2687005
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
    Somers R; Santoro A; Verweij J; Lucas P; Rouëssé J; Kok T; Casali A; Seynaeve C; Thomas D
    Eur J Cancer; 1992; 28A(4-5):855-7. PubMed ID: 1524907
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 13. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine.
    Claudy AL; Lévigne V; Boucheron S
    Dermatology; 1992; 184(1):70-2. PubMed ID: 1559000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ii trial of fotemustine in advanced colorectal cancer.
    Bleiberg H; Becquart D; Michel J; Cavalli F; Gerard B
    Eur J Cancer; 1990; 26(11-12):1260-1. PubMed ID: 2150002
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.
    Curé H; Krakowski I; Adenis A; Tubiana N; Kerbrat P; Roché H; Chevallier B; Lentz MA; Fumoleau P; Chollet P
    Eur J Cancer; 1998 Feb; 34(3):422-3. PubMed ID: 9640234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 20. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.